ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Inflammation"

  • Abstract Number: 0095 • ACR Convergence 2023

    Kynurenine Is a Proinflammatory Metabolite That Activates a Positive Feedback Loop of Rab4A-dependent CD98 Expression and mTORC1 and mTORC2 Activation in SLE

    Thomas Winans1, Nick Huang1, Joshua Lewis1, Xiaojing Wang1, Tamas Faludi1, Daniel Krakko2, Laurence Morel3 and Andras Perl4, 1SUNY Upstate Medical University, Syracuse, NY, 2North Carolina State University, Raleigh, NC, 3University of Texas health San Antonio, San Antonio, TX, 4SUNY, Syracuse, NY

    Background/Purpose: The kynurenine (KYN) pathway has been linked to disease pathogenesis in patients with systemic lupus erythematosus (SLE) (https://pubmed.ncbi.nlm.nih.gov/26366134/). Genetically enforced overexpression of Rab4A activates…
  • Abstract Number: 0525 • ACR Convergence 2023

    Bimekizumab Achieved Sustained Improvements in Efficacy Outcomes in Patients with Axial Spondyloarthritis, Regardless of Prior TNF Inhibitor Treatment: Week 52 Pooled Results from Two Phase 3 Studies

    Marina Nighat Magrey1, Marleen van de Sande2, Maxime Breban3, Filip Van den Bosch4, Carmen Fleurinck5, Ute Massow6, Natasha De Peyrecave7, Thomas Vaux8, Xenofon Baraliakos9 and Helena Marzo-Ortega10, 1Case Western Reserve University, University Hospitals, Cleveland, OH, 2Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute; Amsterdam Rheumatology & Immunology Center (ARC), Academic Medical Center, Amsterdam, Netherlands, 3CHU Ambroise-Paré, Boulogne-Billancourt, Paris, France, 4Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, 5UCB Pharma, Oosterzele, Belgium, 6UCB Pharma, Monheim am Rhein, Germany, 7UCB Pharma, Brussels, Belgium, 8UCB Pharma, Slough, United Kingdom, 9Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 10NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom

    Background/Purpose: In patients (pts) with axial spondyloarthritis (axSpA), tumor necrosis factor inhibitors (TNFi) are the usual first line biologic treatment, yet many pts may experience…
  • Abstract Number: 0884 • ACR Convergence 2023

    Identification of a Mast Cell-high Synovial Pathotype of Osteoarthritis

    Shady Younis, Audrey Bai, heidi Wong, Zelda Love, Qian Wang and William Robinson, Stanford School of Medicine, Stanford, CA

    Background/Purpose: Mast cells in the osteoarthritis (OA) synovium correlate with disease severity. This study aimed to further elucidate the role of mast cells in OA…
  • Abstract Number: 1147 • ACR Convergence 2023

    Blood-Based Biomarkers of Inflammation and Tissue Remodeling Can Discriminate Between Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis and Are Associated with Hand Function

    Helena Port I Linares1, Birte Coppers2, Sara Bayat2, Godonou Elie-Tino2, Larissa Valor-Mendez2, David Simon2, Filippo Fagni2, Giulia Corte2, Anne-Christine Bay-Jensen3, Koray Tascilar2, Axel Hueber4, Verena Schoenau2, Michael Sticherling5, Simon Heinrich6, Daniela Bohr2, Georg Schett7, Arnd Kleyer8, Sigrid Leyendecker6, Signe Holm Nielsen3 and Anna-Maria Liphardt9, 1Nordic Bioscience A/S / University of Copenhagen, Copenhagen, Denmark, 2Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology / Deutsches Zentrum Immuntherapie, Erlangen, Germany, 3Nordic Bioscience, Herlev, Denmark, 4Division of Rheumatology, Klinikum Nürnberg, Paracelsus Medical University / Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology, Nürnberg, Germany, 5Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Dermatology, Erlangen, Germany, 6Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Institute of Applied Dynamics, Erlangen, Germany, 7Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, 8University Hospital Erlangen, Erlangen, Germany, 9Friedrich-Alexander-University Erlangen-Nuremberg, Internal Medicine 3 - Rheumatology and Immunology, University Hospital Erlangen, Erlangen, Germany

    Background/Purpose: Inflammatory musculoskeletal diseases including rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are characterized by physical function impairment due to progressive inflammatory and structural changes.…
  • Abstract Number: 1711 • ACR Convergence 2023

    CD14+ Monocytes Demonstrate a Unique Transcriptional Signature in Macrophage Activation Syndrome, Highlighting a Role for Interferons and Identifying Putative Hemophagocytes in Circulation

    Susan Canny1, Hannah DeBerg2, Griffin Gessay2, Ailing Lu3, Mary Eckert4, Andrea La Bella5, Susan Shenoi6, Joyce Hui-Yuen7, Betsy Barnes8 and Jessica Hamerman2, 1Seattle Children's Hospital/University of Washington, Seattle, WA, 2Benaroya Research Institute, Seattle, WA, 3Feinstein Institutes for Medical Research, Manhasset, NY, 4Seattle Children's Hospital, Seattle, WA, 5Cohen Children's Medical Center, Queens, NY, 6Seattle Childrens Hospital, Mercer Island, WA, 7Division of Pediatric Rheumatology, Cohen Children's Medical Center, Lake Success, NY, 8Northwell Health, Manhasset, NY

    Background/Purpose: Macrophage activation syndrome (MAS) is a potentially fatal complication of rheumatic diseases. MAS is characterized by a dysfunctional hyperinflammatory response in which there is…
  • Abstract Number: 1776 • ACR Convergence 2023

    Macrophage Migration Inhibitory Factor May Help Maintain Tight Junctions in the Gut by Enhancing Occludin Expression

    Shaghayegh Foroozan1 and Nigil Haroon2, 1University Health Network/University of Toronto, Toronto, ON, Canada, 2University of Toronto, University Health Network, Schroeder Arthritis Institute, Department of Medicine/Rheumatology, Toronto, ON, Canada

    Background/Purpose: Axial Spondyloarthritis (AxSpA) is a chronic inflammatory disease with multifactorial origins, primarily affecting the musculoskeletal system. Gut inflammation is seen in the majority of…
  • Abstract Number: 2157 • ACR Convergence 2023

    Exploratory Analysis of the Mechanisms of Action of the Potential Analgesic Effect of Tofacitinib and Adalimumab over Placebo in Patients with Rheumatoid Arthritis: Results of a Mediation Modeling Analysis

    Maxime Dougados1, Peter C. Taylor2, David Gruben3 and Meriem Kessouri4, 1Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris, Paris, France, 2Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 3Pfizer Inc., Groton, CT, 4Pfizer Inc., Paris, France

    Background/Purpose: Pain is the most common symptom reported by patients (pts) with rheumatic disorders, such as RA.1 Improvement in pain with antirheumatic drugs is generally…
  • Abstract Number: 2557 • ACR Convergence 2023

    Clinicopathologic Features of Patients with Giant Cell Arteritis and Thoracic Aorta Repair: A Single Center Experience over Two Decades

    Mahmut Kaymakci1, Nicholas Boire1, Melanie Bois1, Mohanad Elfishawi1, Hannah Langenfeld2, Andrew Hanson2, Cynthia Crowson1, Matthew Koster1, Cornelia M. Weyand3 and Kenneth Warrington1, 1Mayo Clinic, Rochester, MN, 2Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 3Mayo Clinic School of Medicine and Stanford University, Rochester, MN

    Background/Purpose: Patients with giant cell arteritis (GCA) are at increased risk of thoracic aortic aneurysm and dissection. This late complication of the disease is presumed…
  • Abstract Number: 0149 • ACR Convergence 2023

    Impacts of Social Determinants of Health and the Immune System in Adults with Acute-to-Chronic Low Back Pain: An Observational Study

    Colleen Burke1, Michael Brown2, Kenneth Taylor2, Stephanie Danyluk2, Kelley Seebeck2 and Adam Goode3, 1Duke University School of Medicine, Chapel Hill, NC, 2Duke University School of Medicine, Durham, NC, 3Duke University, Durham, NC

    Background/Purpose: Chronic low back pain (cLBP) is common worldwide yet poorly understood due to the combination of biological, psychological, and sociological factors. An individual's social…
  • Abstract Number: 0553 • ACR Convergence 2023

    Serum Isolevuglandin IgG Antibody Concentrations Are Increased in Patients with Systemic Lupus Erythematosus versus Control Subjects and Associated with Lower 24-hour Blood Pressure

    Anastasiia Phothisane1, Shahensha Shaik1, Qiong Wu1, Olivia Posey1, Sean Davies2, Jaya Krishnan1, David Patrick3, C. Michael Stein1 and Michelle Ormseth1, 1Vanderbilt University Medical Center, Nashville, TN, 2Vanderbilt University, Nashville, TN, 3Department of Veterans Affairs, Nashville, TN

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) have a 2-3-fold increased risk of cardiovascular events. A major risk factor for this is hypertension. We previously…
  • Abstract Number: 0913 • ACR Convergence 2023

    Neutrophils in Patients with Systemic Lupus Erythematosus Show Pronounced Inflammatory Signals

    Annie Law1, Chee Jian Pua2, Dianyang Guo3, Chin Teck Ng4, Julian Thumboo1, Andrea Hsiu Ling Low5 and Xiubo Fan1, 1Singapore General Hospital; Duke-NUS Medical School, Singapore, Singapore, 2National Heart Centre, Singapore, Singapore, 3Singapore General Hospital, Singapore, Singapore, 4Singapore General Hospital; Duke-NUS Medical School, Singapore, Malaysia, 5Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore

    Background/Purpose: IFN response, plasmablasts and neutrophils are three hallmarks of systemic lupus erythematosus (SLE). Studies showed that the netting neutrophils stimulated plasmacytoid dendritic cells to…
  • Abstract Number: 1148 • ACR Convergence 2023

    A Comparative Study of Clinical Phenotype in Relation to NOD2 Sub-genotypes in Yao Syndrome

    Ashmia Saif1, Hafsa Nomani2, Frank Hwang2, Jie Yang2 and Qingping Yao2, 1Stony Brook University Hospital, Syosset, NY, 2Stony Brook University, Stony Brook, NY

    Background/Purpose: Yao syndrome (YAOS, OMIM 617321) is formerly designated NOD2-associated autoinflammatory disease. A spectrum of NOD2 mutations have been associated with this disease. Most patients…
  • Abstract Number: 1713 • ACR Convergence 2023

    Prevention of Arthritis Development by Mechanical Unloading Through Inhibition of CCL2 and YAP-mediated Inflammation in the Rat Adjuvant-induced Arthritis Model

    Elisa Dalix1, Mathieu Maalouf1, Robin Caire2, Guillaume Courbon1, Virginie Dumas3, Sylvie Peyroche1, Marie-Thérèse Linossier1, Mireille Thomas1, Charles-Antoine Arthaud1, Arnaud Vanden-Bossche1 and Hubert Marotte4, 1Université Jean Monnet Saint-Étienne, Mines Saint-Etienne, INSERM, Saint-Etienne, France, 2Department of Molecular Medicine, University of Padua School of Medicine, Padua, Italy, 3Laboratory of Tribology and Systems Dynamics, Ecole Nationale d'Ingénieurs de Saint Etienne, Ecole Centrale de Lyon, University of Lyon, Saint-Etienne, France, 4CHU Saint-Etienne, Saint-Etienne, France

    Background/Purpose: Rheumatoid arthritis (RA) is the most common chronic inflammatory rheumatic disease, characterized by synovitis associated with progressive bone loss and joint degradation. The adjuvant-induced…
  • Abstract Number: 1777 • ACR Convergence 2023

    The Effect of the Inflamed Joint Microenvironment on Endothelial Cell Function

    Aenea Brugman1, Órla Tynan2, Dumitru Anton3, Carl Orr4, Viviana Marzaioli5, Douglas Veale6 and Ursula Fearon7, 1Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin; EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, 2Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, 3Molecular Rheumatology Department, Trinity Biomedical Sciences Institute, Trinity College Dublin, EULAR Centre for Arthritis and Rheumatic Diseases, St Vincent University Hospital, University College Dublin, Dublin, Ireland, 4Saint Vincent's University Hospital, Dublin, Ireland, 5Trinity College Dublin and University College Dublin, Dublin, Ireland, 6St.Vincent's University Hosp, Dublin, Ireland, 7Trinity College Dublin, Dublin, Ireland

    Background/Purpose: While common pathogenic mechanisms exist between PsA and RA, distinct vascular morphology has been observed, with PsA displaying a tortuous, dilated, irregular shaped morphology…
  • Abstract Number: 2206 • ACR Convergence 2023

    Increased Frequency of Activated MAIT Cells Expressing the Gut Homing Receptor CCR9 in Patients with Radiographic Axial Spondyloarthritis

    Eric Toussirot1, Caroline Laheurte2, Eléonore Gravelin2, Charline Vauchy3, Marc Puyraveau3 and Philippe Saas4, 1University Hospital of Besancon, Besançon, France, 2INSERM UMR1098, plateforme de biomonitoring, EFS Bourgogne-Franche-Comté, Besançon, France, 3INSERM CIC-1431, Besançon, France, 4INSERM UMR1098, EFS Bourgogne-Franche-Comté, Besançon, France

    Background/Purpose: MAIT (mucosal associated invariant T) cells are involved in mucosa defense against bacteria. This cellular subset is characterized by a semi-invariant αβ TCR and…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 58
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology